Prostate Specific Antigen News and Research

RSS

Black men least likely to get prostate cancer screening even during peak ages of risk

The men most at risk for aggressive prostate cancer - black men with a family history - are the least likely to get screening even during peak ages of risk, researchers say.

5 Feb 2006

Experts counter study's claim - men should continue prostate exams

A man has a one in six chance of being diagnosed with prostate cancer. Each year, more than 230,000 men are diagnosed with the disease. Doctors have traditionally recommended two tests for the early detection of prostate cancer; the prostate specific antigen (PSA) test and digital rectal exam (DRE) are used to detect abnormalities with the prostate gland.

23 Jan 2006

Value of prostate tests dubious

According to new research, men screened for prostate cancer using blood tests or digital examinations die of the disease at much the same rate as those who were not checked.

10 Jan 2006

Screening for prostate cancer may not reduce risk of death

Screening men for prostate cancer may not reduce their risk for dying, according to a new study in the January 9 issue of Archives of Internal Medicine.

9 Jan 2006

The effectiveness of screening for prostate cancer

A screening test for prostate cancer that measures prostate-specific antigen (PSA) levels does not improve survival, researchers at the Veterans Affairs (VA) Connecticut Healthcare System and Yale School of Medicine report in the January 9 Archives of Internal Medicine.

9 Jan 2006

Lifestyle factors affect prostate cancer tests

According to a new study a prostate cancer-screening test may not be that reliable.

12 Dec 2005

Speed of PSA increase matters more than PSA level

In the largest study of its kind to date, Mayo Clinic researchers report that prostate specific antigen (PSA) kinetics, both velocity and doubling time, can be used to predict disease progression and likelihood of death after radical prostatectomy surgery, suggesting that this could be used to guide treatment decisions.

14 Nov 2005

Zyflamend shows promise in the early treatment of prostate cancer

Data from the Columbia University Department of Urology demonstrates that Zyflamend, a unique herbal extract preparation, suppresses the growth of prostate cancer cells and induces prostate cancer cells to self-destruct via a process called "apoptosis."

13 Nov 2005

New therapies for prostate cancer

A Dutch study suggested treating prostate cancer patients with higher doses of radiotherapy significantly improved patient outcome and treatment over a five-year period.

3 Nov 2005

DN-101 may protect against major side effects of chemotherapy

Men with advanced prostate cancer who take an experimental, high-dose vitamin D pill with chemotherapy live about eight months longer than those receiving chemotherapy and placebo, according to a new study.

3 Nov 2005

Role of alpha tocopherol associated protein in prostate cancer

Researchers have identified a protein that disrupts an important signaling pathway in prostate cancer cells and suppresses growth of the cancer.

1 Nov 2005

Benefit of combining radiation and hormone therapy in the treatment of prostate cancer

Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer

1 Nov 2005

Yearly PSA test saves lives

Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.

19 Oct 2005

New prostate cancer test far more accurate

At present in order to predict prostate cancer outcomes, doctors rely on measures that suggest how far the tumour has spread and how abnormal the cancer cells appear under the microscope.

18 Oct 2005

Colorectal cancer screening rates are too low

An intervention program designed to promote screening for colorectal cancer – and thereby decrease the number of cancers diagnosed - failed to increase screening rates in the managed care setting, a University of California - Los Angeles study has found.

10 Oct 2005

Rapid weight gain between the ages of 25 and 40 doubles likelihood of prostate cancer recurrence

Men who gain weight rapidly between the ages of 25 and 40 are twice as likely to have recurrence of prostate cancer after surgery as men without rapid rates of weight gain, researchers from University of Texas M. D. Anderson Cancer Center reported in the October 1 issue of "Clinical Cancer Research."

4 Oct 2005

PSA doubling time is an important indicator of how well a patient will recover from prostate cancer

The clinical outcome for prostate cancer patients who have been treated with hormone therapy and radiation therapy can usually be determined by how rapidly their prostate specific antigen level rises following treatment

3 Oct 2005

Development of aggressive forms of prostate cancer may be influenced by environmental effects that occur early in life

How heavy a man is at the time he is diagnosed with prostate cancer, as well as his history of weight gain, appear to play significant roles in how aggressive his cancer may become, say researchers at the University of Texas M. D. Anderson Cancer Center.

3 Oct 2005

Pomegranate juice shows major promise to combat prostate cancer

The juice of the pomegranate, say researchers at University of Wisconsin Medical School, shows major promise to combat prostate cancer - the most common invasive cancer and the second-leading cause of cancer death in American men.

27 Sep 2005

22 biomarkers that provide a more accurate screening for prostate

Researchers at the University of Michigan Comprehensive Cancer Center have identified a panel of 22 biomarkers that together provide a more accurate screening for prostate cancer than the current prostate specific antigen, or PSA, test.

22 Sep 2005